ARS Pharmaceuticals, Inc. SPRY Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $24.32M-41.1% | $41.32M-30.6% | $59.56M+15.6% | $51.54M+29.3% | $39.86M-21.6% | ||
| $176.65M-13.3% | $203.67M-10.9% | $228.65M+21.2% | $188.59M-20.0% | $235.86M-10.4% | ||
| $28.66M+13.1% | $25.35M-30.5% | $36.45M+45.1% | $25.13M+170% | $9.3M+13.8% | ||
| $23.22M+0.7% | $23.05M+68.9% | $13.65M+2.0% | $13.37M+12.0% | $11.94M+125% | ||
| $6.79M+9.6% | $6.19M-3.5% | $6.42M-13.7% | $7.44M-35.6% | $11.56M+67.9% | ||
| $245.24M-13.9% | $284.9M-15.9% | $338.86M+20.4% | $281.44M-7.4% | $303.86M-9.1% | ||
| $2.29M-7.3% | $2.47M+104% | $1.21M+12.5% | $1.08M0.0% | $1.08M+0.8% | ||
| $14.18M-1.9% | $14.45M-1.9% | $14.73M+13.5% | $12.97M+79.1% | $7.24M-1.8% | ||
| $2.65M-4.8% | $2.79M-4.5% | $2.92M-4.4% | $3.05M-2.6% | $3.13M+0.5% | ||
| $287.57M-12.2% | $327.65M-12.1% | $372.8M+18.9% | $313.47M-4.2% | $327.32M-6.8% | ||
| $48.26M+27.2% | $37.95M-23.8% | $49.77M+12.4% | $44.26M+63.9% | $27.01M+18.2% | ||
| $592K+0.7% | $588K— | —— | —— | —— | ||
| $757K+24.3% | $609K+15.8% | $526K-29.5% | $746K+38.1% | $540K-3.1% | ||
| $978K-13.5% | $1.13M-10.9% | $1.27M+15.0% | $1.1M-17.6% | $1.34M-12.6% | ||
| $49.61M+26.7% | $39.15M-23.1% | $50.88M+11.6% | $45.6M+65.1% | $27.62M+17.8% | ||
| $96.52M+0.2% | $96.37M+0.2% | $96.23M— | —— | —— | ||
| $226.26M+6.0% | $213.39M-5.2% | $225.15M+85.8% | $121.15M+23.2% | $98.34M+4.2% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $10K0.0% | $10K0.0% | $10K0.0% | $10K0.0% | $10K0.0% | ||
| $416.62M+1.9% | $408.73M+1.9% | $400.93M+1.6% | $394.49M+2.2% | $386.14M+1.6% | ||
| -$355.22M-20.6% | -$294.6M-16.3% | -$253.28M-25.3% | -$202.13M-28.5% | -$157.25M-27.5% | ||
| -$96K-177% | $125K+1,886% | -$7K+84.8% | -$46K-164% | $72K-67.3% | ||
| $61.31M-46.3% | $114.26M-22.6% | $147.66M-23.2% | $192.32M-16.0% | $228.97M-10.8% | ||
| $287.57M-12.2% | $327.65M-12.1% | $372.8M+18.9% | $313.47M-4.2% | $327.32M-6.8% | ||
| $8.82M+5.4% | $8.37M+7.5% | $7.78M-10.9% | $8.74M— | —— | ||
| $14.18M-1.9% | $14.45M-1.9% | $14.73M+13.5% | $12.97M+79.1% | $7.24M-1.8% | ||
| $2.65M-4.8% | $2.79M-4.5% | $2.92M-4.4% | $3.05M-2.6% | $3.13M+0.5% | ||
| $176.65M-13.3% | $203.67M-10.9% | $228.65M+21.2% | $188.59M-20.0% | $235.86M-10.4% | ||
| $978K-13.5% | $1.13M-10.9% | $1.27M+15.0% | $1.1M-17.6% | $1.34M-12.6% | ||
| $48.26M+27.2% | $37.95M-23.8% | $49.77M+12.4% | $44.26M+63.9% | $27.01M+18.2% | ||
| $592K+0.7% | $588K— | —— | —— | —— | ||
| $978K-13.5% | $1.13M-10.9% | $1.27M+15.0% | $1.1M-17.6% | $1.34M-12.6% | ||
| $978K-13.5% | $1.13M-10.9% | $1.27M+15.0% | $1.1M-17.6% | $1.34M-12.6% | ||
| $96.52M+0.2% | $96.37M-1.4% | $97.76M+5,786% | $1.66M+2,175% | $73K+73.8% | ||
| $10K0.0% | $10K0.0% | $10K0.0% | $10K0.0% | $10K0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $74.67M+3.5% | $72.14M+0.1% | $72.04M+0.1% | $71.96M+3.7% | $69.38M0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are ARS Pharmaceuticals, Inc.'s total assets?
- ARS Pharmaceuticals, Inc. (SPRY) holds $287.6M in total assets, down 12.1% year over year.
- How much debt does ARS Pharmaceuticals, Inc. have?
- ARS Pharmaceuticals, Inc. carries $96.5M in total debt against $61.3M of shareholders' equity, a debt-to-equity ratio of 1.57.
- How much cash does ARS Pharmaceuticals, Inc. have?
- ARS Pharmaceuticals, Inc. holds $24.3M in cash and equivalents.
- Can ARS Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 4.94 — current assets exceed current liabilities.
- Where does ARS Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
